FAPI-mFS

• Description :

  FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu[1]. FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

• UNSPSC :

  12352209

• Target :

  FAP; Radionuclide-Drug Conjugates (RDCs)

• Type :

  Peptides

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/fapi-mfs.html

• Purity :

  99.78

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(N[C@H](C(N1CCN(CCCOC2=CC=C(N=CC=C3C(NCC(N4[C@H](C#N)CC(F)(F)C4)=O)=O)C3=C2)CC1)=O)CCCCNC(C5=CC(OS(F)(=O)=O)=CC=C5)=O)CN6CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC6

• Molecular Formula :

  C53H69F3N12O15S

• Molecular Weight :

  1203.25

• References & Citations :

  [1]Cui XY, et al., Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024 Jun;630 (8015) :206-213.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported

• CAS Number :

  [3023869-94-2]